van Bon Lenny, Cossu Marta, Scharstuhl Alwin, Pennings Bas W C, Vonk Madelon C, Vreman Hendrik J, Lafyatis Robert L, van den Berg Wim, Wagener Frank A D T G, Radstake Timothy R D J
Department of Rheumatology & Clinical Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht.
Department of Rheumatology.
Rheumatology (Oxford). 2016 Nov;55(11):2066-2073. doi: 10.1093/rheumatology/kew251. Epub 2016 Jul 13.
SSc is a disease characterized by inflammation and fibrosis. Heme Oxygenase-1 (HO-1) is a haem-degrading enzyme that mediates resolution of inflammation and is induced upon mediators abundantly present in SSc. We aimed to assess whether HO-1 expression/function is disturbed in SSc patients and could therefore be contributing to the ongoing inflammation.
In total, 92 SSc patients and 48 healthy controls were included. By measuring total bilirubin in plasma in vivo, HO-activity was assessed. HO-1 expression levels were determined with western blot in monocytes before and after induction of HO-1 with cobalt protoporphyrin (CoPP) with or without CXCL4. Monocyte-derived dendritic cells (DCs) were stimulated with several Toll-like receptor (TLR) ligands with or without pre-stimulation with CoPP for 24 h. Cytokine levels were measured in the supernatants using the Luminex Bead Array.
SSc patients have lower plasma levels of bilirubin, suggestive of an aberrant HO-1 function. We demonstrated low HO-1 expression in immune cells from SSc patients, whereas induction with CoPP was able to restore HO-1 levels in DCs from SSc patients, almost normalizing the increased TLR response observed in SSc. Co-exposure to CXCL4 completely abrogated CoPP-induced HO-1 expression, suggesting that the high CXCL4 levels present in SSc patients block the normal induction of HO-1 and its function.
We demonstrate that HO activity in SSc patients is decreased and show its functional consequences. Since CXCL4 blocks the induction of HO-1 expression, neutralization of CXCL4 in SSc patients could have clinical benefits by diminishing overactivation of immune cells and other anti-inflammatory effects of HO-1.
系统性硬化症(SSc)是一种以炎症和纤维化为特征的疾病。血红素加氧酶-1(HO-1)是一种血红素降解酶,介导炎症消退,在SSc中大量存在的介质作用下被诱导产生。我们旨在评估HO-1的表达/功能在SSc患者中是否受到干扰,以及是否因此导致持续的炎症。
共纳入92例SSc患者和48例健康对照。通过体内测量血浆总胆红素评估HO活性。在用或不用CXCL4的情况下,用原卟啉钴(CoPP)诱导HO-1前后,用蛋白质印迹法测定单核细胞中HO-1的表达水平。用几种Toll样受体(TLR)配体刺激单核细胞来源的树突状细胞(DC),在用或不用CoPP预刺激24小时的情况下。使用Luminex微珠阵列测量上清液中的细胞因子水平。
SSc患者血浆胆红素水平较低,提示HO-1功能异常。我们证明SSc患者免疫细胞中HO-1表达较低,而用CoPP诱导能够恢复SSc患者DC中的HO-1水平,几乎使SSc中观察到的TLR反应增加正常化。同时暴露于CXCL4完全消除了CoPP诱导的HO-1表达,表明SSc患者中存在的高CXCL4水平阻断了HO-1的正常诱导及其功能。
我们证明SSc患者的HO活性降低并显示了其功能后果。由于CXCL4阻断HO-1表达的诱导,中和SSc患者体内的CXCL4可能通过减少免疫细胞的过度活化和HO-1的其他抗炎作用而具有临床益处。